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Objectives: EarlyCDT®-Lung may enhance detection of early stage lung cancer by aiding physicians in
assessing high-risk patients through measurement of biological markers (i.e., autoantibodies). The test’s
performance characteristics in routine clinical practice were evaluated by auditing clinical outcomes of
1613 US patients deemed at high risk for lung cancer by their physician, who ordered the EarlyCDT-Lung
test for their patient.
Methods: Clinical outcomes for all 1613 patients who provided HIPAA authorization are reported. Clin-
ical data were collected from each patient’s treating physician. Pathology reports when available were
reviewed for diagnostic classification. Staging was assessed on histology, otherwise on imaging.
Results: Sixmonth follow-up for the positives/negatives was 99%/93%. Sixty-one patients (4%) were iden-
tified with lung cancer, 25 of whom tested positive by EarlyCDT-Lung (sensitivity =41%). A positivelood test
umor-associated antigens
EarlyCDT-Lung test on the current panel was associated with a 5.4-fold increase in lung cancer incidence
versus a negative. Importantly, 57% (8/14) of non-small cell lung cancers detected as positive (where
stage was known) were stage I or II.
Conclusions: EarlyCDT-Lung has been extensively tested and validated in case–control settings and has
now been shown in this audit to perform in routine clinical practice as predicted. EarlyCDT-Lung may be
a complementary tool to CT for detection of early lung cancer.
he A© 2013 T
. Introduction
Lung cancer currently causes more deaths from cancer in the
orld than any other tumor type, and projections over the next 20
ears indicate this is likely to continue unless substantial progress
s made in areas such as screening, early detection, treatment and
revention. TheNational Lung Screening Trial (NLST) addressed the
uestion of CT screening and early detection in a large random-
zed trial and reported a 20% reduction in lung cancer mortality
1]. This provided level 1 evidence and confirmation of previous
on-randomized trials of CT screening [2–5] that reported more
etection of early stage disease and prolonged survival.
∗ Corresponding author at: Royal Derby Hospital, Uttoxeter Road, Derby DE22
DT, UK. Tel.: +44 01332 724881; fax: +44 01332 724880.
E-mail address: John.Robertson@nottingham.ac.uk (J.F.R. Robertson).
169-5002 © 2013 The Authors. Published by Elsevier Ireland Ltd.
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Open access under CC BYuthors. Published by Elsevier Ireland Ltd.
The fact that we now know that screening and early detection
saves lives from lung cancer is in many ways only the start of the
process of developing a cost effective early detection program. A
screening program based only upon CT as demonstrated by the
NLST study has numerous problems, including a high number of
benign nodules identified (i.e., false positives; e.g., 96.4% of the pos-
itive results in the NLST study were benign) [1,2,6,7], the lingering
question of what to do after 3 annual screens, and the fact that only
∼30% of all lung cancer patientswouldmeet the NLST entry criteria
(i.e., 55–74 years of age, ≥30 pack-years smoking history, and if an
ex-smoker, must have quit within the last 15 years) [1]. One recent
publication from a single US center focused on patients presenting
with early stage lung cancers and aimed to address the question of
thepercentageof patientswith early stage lung cancerwho fulfilled
the NLST criteria. Based on 267 patients with early stage disease,
less than half met the NLST high risk criteria. Since the majority of
Open access under CC BY-NC-ND license.these patients were not considered high-risk by the NLST criteria,
they would not be covered under current screening paradigms [8].
It therefore seems that a requirement for an effective early
detection program would be a biological test that would increase
-NC-ND license.
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Table 1
Breakdown of age, gender and 5-year lung cancer risk [10] for the groups tested on the 6AAB and 7AAB EarlyCDT-Lung panels.
Overall 6AAB 7AAB
Total number
of patients
Age (median;
range)
Mean 5-year
lung cancer
risk (number
assessablea)
Total number
of patients
Age (median;
range)
Mean 5-year
lung cancer
risk (number
assessablea)
Total number
of patients
Age (median;
range)
Mean 5-year
lung cancer
risk (number
assessablea)
Male 676 (42%) 63; 30–95 4.4% (613) 363 (48%) 63; 30–85 4.5% (332) 313 (36%) 62; 38–95 4.1% (281)
62; 31–92 2.5% (350) 548 (64%) 60; 35–89 1.9% (518)
ear lung cancer risk could not be calculated.
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Table 2
Six-month follow-up percentages for patients testing positive and negative by
EarlyCDT-Lung.
Positive follow-up % Negative follow-up %
Overall 99 93Female 937 (58%) 61; 31–92 2.2% (868) 389 (52%)
a In some cases, patient demographic information was incomplete; therefore, 5-y
he pre-test probability of lung cancer in a high risk population –
he pre-test probability being based either on demographic factors
e.g., age and smokinghistory), imagingfindings (e.g., lungnodules)
r both. A biological test that is performed on a peripheral blood
amplewouldhave clear advantages, includingpatient compliance,
onvenience and cost savings. EarlyCDT-Lung is a blood test that
easures autoantibodies to lung cancer-associated antigens. Itwas
eveloped to aid physicians in the early detection of lung cancer in
high-risk population. EarlyCDT-Lung was introduced clinically in
limitedmanner; as part of the limited release of the test a clinical
udit programwas established for individualswhogave consent for
ollow-up in accordance with the HIPAA Privacy Rule. The primary
urpose of the audit was to confirm that the characteristics of the
est, as reported in the training and validation case–control stud-
es, were reproducible in routine clinical practice. This manuscript
eports clinical outcomes at 6months following EarlyCDT-Lung for
he first ∼1600 patients whose physicians ordered the test and
here the patient gave informed consent to be part of the audit
rogram.
. Patients and methods
.1. Audit population
The first 1699 patients for whom US physicians ordered
arlyCDT®-Lung are described here. The tests were ordered by
10 unique physicians in 720 different practices throughout 48 US
tates. As this is an audit of clinical practice, we are reporting the
hysicians’ use of the test and not a prospective study in a pop-
lation defined by inclusion and exclusion factors. Of these 1699
atients, 1613 (95%) signed a HIPAA authorization permitting the
rdering physician to disclose health information to Oncimmune®,
nd it is this group that has been followed in this audit for clinical
utcomes to confirm EarlyCDT-Lung test characteristics in routine
ractice.
The EarlyCDT-Lung panel wasmodified in November 2010 from
6 autoantibody (6AAB) panel to a panel measuring 7 autoanti-
odies (7AAB) to improve specificity of the test, which has been
reviously reported [9]. This report does not focus again on this
oint, but the inclusion of patients tested on both the 6AAB and
AAB panels in this dataset does allow comparison of these two
ub-groups in routine practice. The patient demographics of the
verall audit population (n=1613) and the6AAB (n=752) and7AAB
n=861) panel groups are shown in Table 1 along with the 5-year
ung cancer risk for each group,whichwas calculated using amodi-
ed version of the Spitzmodel that takes into account demographic
isk factors such as gender, age and smoking history [10].
.2. EarlyCDT-Lung assayEarlyCDT®-Lung is a physician-ordered blood test that serves as
tool to aid in early detection of lung cancer in high-risk patients.
he test is performed only in Oncimmune’s CLIA laboratory (De
oto, KS). The technology has been extensively validated and6AAB 100 97
7AAB 98 91
has been shown to be technically and clinically robust [9,11–13].
EarlyCDT-Lung detects the presence of AABs to a panel of lung
cancer-associated antigens using a semi-automated indirect ELISA-
based method. A test result was reported as positive if the antigen
titration series showed a dose response and any one or more AAB
levels were elevated above the clinical cut-off.
Testing of all patient specimens by EarlyCDT-Lung was per-
formed in Oncimmune’s CLIA laboratory, including the data
handling and calculation of the test result, which was performed
by the Oncimmune laboratory information management system
(LIMS); final test results were generated and reported to individual
physicians. All EarlyCDT-Lung tests were performed prospectively
upon receiving the physician’s order, and the results were reported
back to the physician without knowledge of the patient’s clinical
outcome, which was subsequently obtained as part of this audit.
2.3. Audit plan
Demographic data were requested as part of the EarlyCDT-Lung
test requisition form. These data were considered in the audit.
Additionally, clinical follow-up data on patients who provided
HIPAA authorization were collected from their treating physi-
cian. In patients with a positive EarlyCDT-Lung test, contact was
made with physicians immediately following the reporting of the
EarlyCDT-Lung result andmaintained until the physician indicated
that a diagnosis had been reached or a follow-up plan decided
(i.e., anticipated timing of imaging, biopsy, surgery, etc.); this was
usually within 2–3 months of the EarlyCDT-Lung test. Subsequent
follow-up on patients with a positive EarlyCDT-Lung test was then
structured around the physician-described follow-up plan. Infor-
mation concerning whether a patient was diagnosed with cancer
was requested from physicians for all individuals regardless of
test result at 6 months after the test. This timeframe was cho-
sen (i) because it was felt to represent a timeframe within which
the immediate value of a positive test result could be assessed,
(ii) it allowed time for all patients with a negative EarlyCDT-Lung
test to present with lung cancer in order to reduce the chance of
observer bias in preferentially following up individualswith a posi-
tive EarlyCDT-Lung test result. One patient with a positive test was
diagnosed just outside the 6 month period: this patient has been
included since they were being actively investigated during the six
month period for a lesion identified on imaging as being suspicious
of lung cancer. The overall percentage of individuals followed-up
at six months in the positive and negative EarlyCDT-Lung groups
was 99% and 93%, respectively (Table 2); these data are also further
broken down by the 6AAB and 7AAB groups (Table 2).
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Total Number of Paents 
1699 
Signed HIPAA Authorizaon 
1613 (95%) 
Did Not Sign HIPAA 
86 (5%) 
No Follow-up
Posive EarlyCDT-Lung 
222 
Negave EarlyCDT-Lung 
1377 
Invalid EarlyCDT-Lung 
14 
6AAB 
139 
7AAB 
83 
6AAB 
613 
7AAB 
764 
Lung 
Cancer 
12 
Not Lung 
Cancer 
127 
Lung 
Cancer 
13 
Not Lung 
Cancer 
70
Lung 
Cancer 
14 
Not Lung 
Cancer 
599
Lung 
Cancer 
22 
Not Lung 
Cancer 
742
NFPT TP FP FP FN NTNT
F test panel and clinical outcome. [6AAB: 6 autoantibody EarlyCDT-Lung panel; 7AAB: 7
a negatives; FN: false negatives.]
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Table 3
Clinical performance of the 6AAB and 7AABpanels, calculated from the clinical audit
dataset with 6 month follow-up for all patients.
Specificity (%; 95% CI)a Sensitivity (%; 95% CI)b PPV
Overall 1341/1538 (87%; 85–89%) 25/61 (41%; 29–54%) 1 in 8.9 (11%)
6AAB 599/726 (83%; 79–85%) 12/26 (46%; 27–67%) 1 in 11.6 (9%)
7AAB 742/812 (91%; 89–93%) 13/35 (37%; 21–55%) 1 in 6.4 (16%)
95% CI: 95% confidence interval, calculated in SAS using the Clopper-Pearson exact
method.
a The 7AAB panel shows a highly statistically significant improvement in speci-
ficity of EarlyCDT-Lung (p<0.0001).ig. 1. Breakdown of patients considered in this audit, by EarlyCDT-Lung result,
utoantibody EarlyCDT-Lung panel; TP: true positives; FP: false positives; TN: true
This report, therefore, focuses on the initial presentation and
utcomes of all patients within 6 months following testing
y EarlyCDT-Lung. Wherever possible, histology/cytology reports
ere reviewed and considered for diagnostic classification; some
atients did not have a tissue diagnosis but were diagnosed, for
xample, based on imaging reports. It was decided from the start
f the audit that if a physician diagnosed a lung cancer, then only in
ircumstances where there was specific proof to the contrary, and
his was confirmed by an external expert, would the diagnosis by
he treating physician not be accepted; this rule was applied for all
atients regardless of EarlyCDT-Lung result.
.4. Statistical analyses
The EarlyCDT-Lung test performance is presented in terms of
tandard test characteristics, such as sensitivity (the percentage
f true positives) and specificity (the percentage of true nega-
ives). Positive predictive value (PPV; the probability of cancer
iven a positive test result) was also calculated. These analyses
ere performed using Microsoft Excel. Comparison of sensitivity
nd specificity of EarlyCDT-Lung for the 6AAB and 7AAB groups is
lso presented; these comparisons were made using chi-squared
ests.
. Results
Of the 1613 test results, there were 14 patients where the test
esult was declared ‘Invalid’ (by pre-determined criteria, as out-
ined in the laboratory’s standard operating procedures) on the
eport sent to the treating physician. There were 222 patients who
ested positive (14%) and 1377 tested negative (86%) (Fig. 1). The
ercent positive for the 6AAB and 7AAB panels was 18% (n=139)
nd 10% (n=83), respectively.
Sixty-one patients (4%)were diagnosedwith lung cancerwithin
months following EarlyCDT-Lung, 25 of whom tested positive
y EarlyCDT-Lung (i.e., 25 true positives and 36 false negatives;
ensitivity =41%). There were 1341/1538 patients not diagnosed
ith lung cancer who tested negative (i.e., 1341 true negatives and
97 false positives; specificity =87%). The correlation between the
arlyCDT-Lung result and clinical outcome in terms of diagnosisb The sensitivities of the 6AAB and 7AAB panels were not statistically different
(p=0.5).
within six months after having taken the EarlyCDT-Lung test
is shown in Fig. 1 and Table 3. Comparing performance of the
two panels, the 7AAB panel showed highly statistically significant
(p<0.0001) improvements in specificity over the 6AAB panel with
91% specificity for the 7AAB panel (i.e., 742 true negatives and 70
false positives) and 83% specificity for the 6AAB panel (i.e., 599 true
negatives and 127 false positives). The sensitivities of the 6AAB
and 7AAB panels were not statistically different (p=0.5): 46% (i.e.,
12 true positives and 14 false negatives) versus 37% (i.e., 13 true
positives and 22 false negatives), respectively. The improvement
in PPV offered by the 7AAB panel was nearly 2× better than the
previous 6AAB panel: 16% (1 in 6.4) for the 7AAB panel versus 9%
(1 in 11.6) for the 6AAB panel (Table 3).
Of the 61 lung cancer cases diagnosed, 46 (75%) were non-small
cell lung cancer (NSCLC), 4 (7%) were small cell lung cancer (SCLC),
1 (2%) wasmixed NSCLC-SCLC, and typewas unknown for 10 (16%)
cases (Table 4). Of the 46 NSCLCs with a histologic diagnosis, 26
(57%) were early-stage (stage I or II), 16 (35%) were late-stage
(stage III or IV) and 4 (9%) were stage unknown (Table 4). Impor-
tantly, 57% (8/14) of NSCLCs detected as positive by EarlyCDT-Lung
(where stage was known) were early-stage. Stage was unknown
for an additional 2 NSCLCs detected by EarlyCDT-Lung. Thirty-two
NSCLCs were adenocarcinoma and 14 were squamous cell carci-
noma. Only four cases of small cell lung cancer were diagnosed,
which is too few to allow for further evaluation. Of the 10 patients
with unknown type of lung cancer (Table 4), 9were diagnosed clin-
ically due to the patient’s condition being too fragile for biopsy
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Table 4
Breakdown of cancer type/sub-type and stage of disease for the 61 lung cancer cases.
Lung cancer type/sub-type Number Stage
I II III IV N/A
NSCLC
Adenocarcinoma 32 (52%) 13 (41%) 1 (3%) 8 (25%) 7 (22%) 3 (9%)
Squamous 14 (23%) 8 (57%) 4 (29%) 1 (7%) – 1 (7%)
Total (NSCLC) 46 21 (46%) 5 (11%) 9 (20%) 7 (15%) 4 (9%)
SCLC
Small cell lung cancer (SCLC) 4 (7%) – – 3 (75%) 1 (25%) –
Other
Mixed SCLC+NSCLC 1 (2%) – – 1 (100%) – –
Unknown typea 10 (16%) 3 (30%) 2 (20%) – 1 (10%) 4 (40%)
Overall total 61 24 (39%) 7 (11%) 13 (21%) 9 (15%) 8 (13%)
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n=4), an inconclusive biopsy (n=3) or the patient refused diag-
ostic procedures (n=2), and in 1 case the information was not
ccessible due to the patient’s records being in storage.
. Discussion
The performance characteristics of the EarlyCDT-Lung test in
linical practice, as demonstrated by this prospective audit,mirrors
hat of the extensive case–control training and validation stud-
es previously reported [9,12–14]. This audit has confirmed that
arlyCDT-Lung detects all types of lung cancer, all stages of the dis-
ase, and performs in clinical practice with the same sensitivity
nd specificity measured in the case–control studies. This is, there-
ore, the first autoantibody test that detects early stage lung cancer
s shown with prospective validation data on a large number of
ndividuals from a routine clinical practice setting.
Furthermore, the previously reported change that was made to
he panel in November 2010 (6AAB panel to 7AAB panel) [9] has
roven in routine clinical practice to have reduced the number of
alse positives (i.e., increased specificity), while maintaining the
ame ability to detect lung cancers (i.e., sensitivity). This resulted
n an increased PPV of EarlyCDT-Lung in routine clinical practice
rom 9% (1 in 11.6) with the 6AAB panel to 16% (1 in 6.4) with the
AAB panel (Table 3). For patients with a negative EarlyCDT-Lung
esult on the current 7AAB panel, 22/764 (3%) were found to have
lung cancer (i.e., 1 in 34.7). Thus, a positive result on the current
AAB EarlyCDT-Lung test panel represents, on average, a 5.4-fold
ncreased incidence of lung cancer within 6 months.
According to the National Cancer Institute’s SEER statistics, 39%
f lung cancers are adenocarcinoma, 21% are squamous cell, and
4% are SCLC [15]. With the exception of a slightly higher propor-
ion of adenocarcinoma (52%) and lower proportion of SCLC (7%) in
ur group, our audit findings are in line with the SEER statistics’
reakdown by histological sub-type, confirming that the cohort
resented here is representative of a high-risk (for lung cancer)
opulation and is not heavily biased toward any particular type of
ung cancer. These audit data also confirm the case–control vali-
ation results that EarlyCDT-Lung detects all sub-types of lung
ancer.
EarlyCDT-Lunghas been shown in case–control studies andnow
n this clinical audit to also detect early-stage lung cancer. In the
roup evaluated for this audit where stage was known, 57% (8/14)
f NSCLCs detected by EarlyCDT-Lung were early-stage.
The results presentedon theoverall performance characteristics
f the test (e.g., specificity and sensitivity) confirm that in routine
linicalpracticeEarlyCDT-Lungperformsaspredicted fromourpre-
iously reported large case–control studies. The audit results havewere too fragile for biopsy, had an inconclusive biopsy, declined further testing or
highlighted the value of the test to physicians as an aid to detection
of early lung cancer.
Until recently, there were no significant biological markers
related to the individual or the lung cancer that could be mea-
sured as a blood test and used in clinical practice. EarlyCDT-Lung
measures AABs to lung cancer-associated antigens; it is biologi-
cally based and has been reported to be independent of a patient’s
demographics and smoking history [16]. Its high specificity and
PPV make it a potentially complementary tool for use in conjunc-
tion with CT to evaluate a patient at high risk for lung cancer. For
example, if a pulmonary nodule is identified on a CT scan and the
EarlyCDT-Lung test is positive, the probability of malignancy is sig-
nificantly increased (manuscript in preparation). In addition, if a
patientwho falls just outside theNLST criteria for CT screening tests
positive by EarlyCDT-Lung, then their risk of lung cancer would
be increased to a level that would now make them appropriate
for CT screening. However, it is important to note that due to the
relatively low sensitivity (∼41%) of EarlyCDT-Lung, a negative test
result does not rule out lung cancer in either scenario; in the case
of the pulmonary nodule and a negative EarlyCDT-Lung result, the
physician would continue to follow the current recommendations
for follow-up CT scanning per the Fleischner Guidelines [17], and
in the second scenario with a negative EarlyCDT-Lung result, the
physician would continue monitoring the patient’s health accord-
ing to standard procedures, as theywould have done in the absence
of the EarlyCDT-Lung test.
Two prospective clinical trials are currently on-going – one in
the US (assessing the value of the test in conjunction with CT) and
a second in the UK (assessing the value of the test as a pre-CT
screening tool).
5. Summary
This is the first biologically based blood test for lung can-
cer detection that has been extensively tested and validated in
case–control settings and has now been shown to perform as pre-
dicted in clinical practice. The population on whom the test was
used was high risk with 4% diagnosed with lung cancer within 6
months following EarlyCDT-Lung. A positive result on the current
7AAB EarlyCDT-Lung test was associated with a 5.4-fold increase
in incidence of lung cancer compared to a negative test.
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